Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$8.85 +4.9%	$7.67	$4.15 ▼ $9.50	$1.85B	1.75	2.82 million shs	4.79 million shs
FOLD Amicus Therapeutics	$7.68 +2.1%	$8.05	$6.20 ▼ $12.65	$2.36B	0.79	2.65 million shs	4.49 million shs
LGND Ligand Pharmaceuticals	$109.86 -1.4%	$108.10	$69.51 ▼ $129.90	$2.12B	1.07	119,833 shs	105,777 shs
MYGN Myriad Genetics	$7.41 +2.9%	$9.11	$7.11 ▼ $29.30	$682.99M	1.87	965,721 shs	4.22 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	+1.44%	+7.93%	+7.38%	+5.24%	+97.66%
FOLD Amicus Therapeutics	+1.76%	+8.83%	-10.79%	-21.58%	-26.63%
LGND Ligand Pharmaceuticals	+2.30%	+4.61%	+3.49%	-6.34%	+58.08%
MYGN Myriad Genetics	-4.00%	-3.10%	-18.92%	-42.58%	-63.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCRX BioCryst Pharmaceuticals	4.46 of 5 stars	4.4	2.0	4.2	3.2	1.7	0.6
FOLD Amicus Therapeutics	4.3738 of 5 stars	3.4	2.0	4.3	4.0	0.8	1.9
LGND Ligand Pharmaceuticals	4.3922 of 5 stars	3.5	0.0	4.4	3.9	2.5	1.9
MYGN Myriad Genetics	4.1007 of 5 stars	4.1	2.0	4.1	1.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.88	Moderate Buy	$16.13	82.20% Upside
FOLD Amicus Therapeutics	2.78	Moderate Buy	$16.75	118.10% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.43	33.29% Upside
MYGN Myriad Genetics	2.19	Hold	$20.61	178.10% Upside

Current Analyst Ratings Breakdown

Latest MYGN, FOLD, LGND, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	BCRX BioCryst Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$20.00
4/17/2025	MYGN Myriad Genetics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
4/11/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00 ➝ $11.00
4/10/2025	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/10/2025	LGND Ligand Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$143.00
4/9/2025	MYGN Myriad Genetics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
4/1/2025	MYGN Myriad Genetics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$24.00 ➝ $20.00
3/12/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$11.50 ➝ $12.50
3/4/2025	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$14.00 ➝ $11.50
3/3/2025	MYGN Myriad Genetics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underperform ➝ Underperform	$13.00 ➝ $11.00
2/25/2025	BCRX BioCryst Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $11.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$450.71M	4.10	N/A	N/A	($2.22) per share	-3.99
FOLD Amicus Therapeutics	$528.30M	4.47	N/A	N/A	$0.63 per share	12.19
LGND Ligand Pharmaceuticals	$167.13M	12.67	$4.50 per share	24.39	$40.39 per share	2.72
MYGN Myriad Genetics	$837.60M	0.82	N/A	N/A	$9.53 per share	0.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	-$226.54M	-$0.43	N/A	N/A	N/A	-30.01%	N/A	-24.06%	5/5/2025 (Estimated)
FOLD Amicus Therapeutics	-$151.58M	-$0.18	N/A	17.86	1.51	-10.62%	12.44%	2.60%	5/1/2025 (Estimated)
LGND Ligand Pharmaceuticals	$52.15M	-$0.16	43.77	29.61	N/A	29.68%	4.95%	4.39%	5/8/2025 (Estimated)
MYGN Myriad Genetics	-$263.30M	-$1.41	N/A	N/A	N/A	-14.09%	-4.51%	-3.07%	5/6/2025 (Estimated)

Latest MYGN, FOLD, LGND, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	N/A	N/A	N/A	$37.84 million	N/A
5/6/2025	Q1 2025	MYGN Myriad Genetics	-$0.05	N/A	N/A	N/A	$200.37 million	N/A
5/5/2025	Q1 2025	BCRX BioCryst Pharmaceuticals	-$0.07	N/A	N/A	N/A	$126.83 million	N/A
5/1/2025	Q1 2025	FOLD Amicus Therapeutics	$0.08	N/A	N/A	N/A	$136.32 million	N/A
2/25/2025	Q4 2024	MYGN Myriad Genetics	$0.03	-$0.09	-$0.12	-$0.47	$210.35 million	$210.60 million
2/24/2025	Q4 2024	BCRX BioCryst Pharmaceuticals	-$0.07	-$0.13	-$0.06	-$0.13	$126.64 million	$131.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.78	2.73
FOLD Amicus Therapeutics	2.01	3.39	2.42
LGND Ligand Pharmaceuticals	N/A	12.49	11.81
MYGN Myriad Genetics	0.05	1.90	1.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
MYGN Myriad Genetics	99.02%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	4.80%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	5.90%
MYGN Myriad Genetics	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	208.96 million	197.19 million	Optionable
FOLD Amicus Therapeutics	480	307.24 million	292.23 million	Optionable
LGND Ligand Pharmaceuticals	80	19.28 million	17.78 million	Optionable
MYGN Myriad Genetics	2,600	92.17 million	89.12 million	Optionable

MYGN, FOLD, LGND, and BCRX Headlines

Recent News About These Companies

Myriad Genetics (NASDAQ:MYGN) Reaches New 1-Year Low - What's Next?

April 30 at 10:00 AM | marketbeat.com

Myriad Genetics (MYGN) Survey Highlights Views on Mental Health Medication | MYGN Stock News

April 30 at 9:34 AM | gurufocus.com

Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

April 30 at 8:00 AM | globenewswire.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts

April 28 at 2:16 AM | marketbeat.com

Wells Fargo & Company MN Purchases 87,659 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

April 26, 2025 | marketbeat.com

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer ...

April 25, 2025 | gurufocus.com

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer ...

April 25, 2025 | gurufocus.com

Myriad Genetics Unveils Promising Clinical Data on Precise MRD Test for Oligometastatic Clear-Cell Renal Cell Carcinoma at AACR Annual Meeting

April 25, 2025 | quiverquant.com

Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting

April 25, 2025 | globenewswire.com

Myriad Genetics Q3 EPS Forecast Increased by Leerink Partnrs

April 25, 2025 | marketbeat.com

Invesco Ltd. Has $10.55 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

April 25, 2025 | marketbeat.com

Analysts Set Expectations for Myriad Genetics Q3 Earnings

April 24, 2025 | americanbankingnews.com

Leerink Partners Sticks to Its Hold Rating for Myriad Genetics (MYGN)

April 23, 2025 | markets.businessinsider.com

Myriad Genetics (NASDAQ:MYGN) Hits New 52-Week Low - Here's Why

April 23, 2025 | marketbeat.com

Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?

April 22, 2025 | zacks.com

Myriad says GeneSight Psychotropic Test led to fewer hospitalizations in study

April 21, 2025 | msn.com

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

April 21, 2025 | globenewswire.com

Federated Hermes Inc. Sells 47,999 Shares of Myriad Genetics, Inc. (NASDAQ:MYGN)

April 21, 2025 | marketbeat.com

Renaissance Technologies LLC Grows Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

April 20, 2025 | marketbeat.com

JPMorgan Chase & Co. Has $5.83 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

April 20, 2025 | marketbeat.com

Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Bought by XTX Topco Ltd

April 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN, FOLD, LGND, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$8.85 +0.41 (+4.86%)

As of 04:00 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Amicus Therapeutics NASDAQ:FOLD

$7.68 +0.16 (+2.13%)

As of 04:00 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$109.86 -1.52 (-1.36%)

As of 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Myriad Genetics NASDAQ:MYGN

$7.41 +0.21 (+2.92%)

As of 04:00 PM Eastern

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time